hyperuricemia
Conditions
Interventions
febuxostat + life style modification
life style modification
Sponsors
UFO study Investigators
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: (1) serum urate levels higher than 7.0 mg/dl (2) not treated with urate reducing drugs for 1 month (3) other complications including hypertension, dyslipidemia and diabetes are in stable (4)written informed consent obtained from the participants
Exclusion criteria
Exclusion criteria: (1) patients with history of gout (2) patients with malignancy, or other serious illness (3) patients with allergy to febuxostat (4) patients treated with mercaptopurine or azathioprine (5) patients not recognized as appropriate to participate (6) patients under insulin treatment (7) serum creatinine levels higher than 1.5 mg/dl (8) patients with inflammatory disease such as rheumatic diseases or inflammatory bowel diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum high sensitivity C-reactive protein (CRP) | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Changes of HOMA-IR between two groups (2) Changes of IMT, PWV (3) Effects on factors of metabolic syndrome (abdominal, blood pressure, fat, blood glucose) (4) Change of serum uric acid levels and achiving less than 6.0mg/dl of uric acid levels, (5) Changes of eGFR (6) Changes of albuminuria/creatinine (7) Changes of serum and urine biomarkers | — |
Countries
Japan
Contacts
Public ContactKoyama, Hidenori
Hyogo College of Medicine Department of Internal Medicine, Division of Diabetes, Endocrinology and Metabolism
Outcome results
None listed